Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | February 12, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date February 12, 2026 · Filed March 04, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 13,667 |
Reported balance
After 2026-02-12 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-02-12 · Grant · Acquired 13,667 · Balance 13,667 F2: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4. F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 162 |
Reported balance
After 2026-02-12 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2026-02-12 · Grant · Acquired 162 · Balance 162 F2: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4. F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. |
| Common StockSEC Table I · non-derivative | Direct | 15,092.351 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 15,092.351 F1: Includes 184 vested but deferred restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 184 vested but deferred restricted stock units.
F2: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4.
F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 197 | $0.00 Strike: $505.53 | $0.00 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · derivative · entry 20 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 197 shares Expires 2032-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2026. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 183 | $0.00 Strike: $544.08 | $0.00 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · derivative · entry 19 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 183 shares Expires 2031-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2025. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 483 | $0.00 Strike: $206.94 | $0.00 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · derivative · entry 18 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 817 | $0.00 Strike: $178.26 | $0.00 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · derivative · entry 17 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 817 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2023. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 719 | $0.00 Strike: $141.60 | $0.00 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · derivative · entry 16 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 719 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2022. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 197 | $505.53 | $99,589.41 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 13 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,092.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · balance_after: Includes 184 vested but deferred restricted stock units. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 183 | $544.08 | $99,566.64 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 12 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,895.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 483 | $206.94 | $99,952.02 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 11 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,712.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 817 | $178.26 | $145,638.42 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 10 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,229.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 719 | $141.60 | $101,810.40 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 9 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,412.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 4,180 | $0.00 Strike: $178.26 | $0.00 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · derivative · entry 15 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,180 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning on February 14, 2019. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,191 | $0.00 Strike: $141.60 | $0.00 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · derivative · entry 14 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,191 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning on February 14, 2018. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 40 | $629.86 | $25,194.50 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 8 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,693.351 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 689 | $629.09 | $433,443.42 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 7 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,733.351 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $628.755 to a high of $629.615 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,694 | $628.22 | $1,692,426.84 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 6 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,422.351 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $627.74 to a high of $628.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,288 | $626.26 | $806,618.24 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 5 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,116.351 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $626.045 to a high of $628.38 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 204 | $625.24 | $127,549.43 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 4 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,404.351 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $624.89 to a high of $625.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 456 | $623.76 | $284,433.74 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 3 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,608.351 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $623.28 to a high of $624.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 4,180 | $178.26 | $745,126.80 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 2 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,064.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,191 | $141.60 | $168,645.60 |
DisclosureSEC source: 0000874716-26-000033 · wk-form4_1771542024.xml · nonDerivative · entry 1 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,884.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 1,508 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 15 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,508 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. F12 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. F12 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 184 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 14 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550 Underlying: Common Stock · 184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F11 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F11 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 13 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602 Underlying: Common Stock · 301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 94 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 12 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94 Underlying: Common Stock · 94 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2024. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2024. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2024. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 92 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 11 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning on February 14, 2023. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning on February 14, 2023. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning on February 14, 2023. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 184 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 10 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550 Underlying: Common Stock · 184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. F7 · derivative.exercise_date: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. F7 · derivative.expiration_date: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 974 | $629.35 | $612,986.90 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · nonDerivative · entry 7 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,693.351 F3 · price: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. F4 · balance_after: Includes 184 vested but deferred RSUs. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 184 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · nonDerivative · entry 6 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,667.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: 2. Represents Restricted Stock Units ('RSU') that were granted on February 14, 2025, were deferred in accordance with the Issuer's Deferred Compensation Plan and have vested. Upon vesting, these RSUs were recorded in an account under such Plan and represents a contingent right to receive one share of Issuer common stock that is payable as soon as practicable after the reporting person's separation of service with the Issuer or a date specified by the reporting person. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,508 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · nonDerivative · entry 5 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,483.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 184 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · nonDerivative · entry 4 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,975.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · nonDerivative · entry 3 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,791.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 94 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · nonDerivative · entry 2 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,490.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 92 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · nonDerivative · entry 1 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,396.351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 17.386 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on September 30, 2025 and December 31, 2025. There are a total of 137.351 shares held in the ESPP which has been reduced by 0.005 shares due to a rounding calculation of previously issued fractional shares. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,580 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 9 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,580 Underlying: Common Stock · 1,580 shares Expires not disclosed F6 · derivative.exercise_price: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F6 · derivative.exercise_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F6 · derivative.expiration_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 4,739 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 8 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,739 Underlying: Common Stock · 4,739 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Mar 4, 2026 02:45 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000046 · wk-form4a_1772592318.xml · derivative · entry 3 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F2 · security: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Mar 4, 2026 02:45 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 13,667 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000046 · wk-form4a_1772592318.xml · derivative · entry 2 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 13,667 shares Expires 2036-02-11 F2 · security: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 87.892 | $649.85 | $57,116.68 |
DisclosureSEC source: 0000874716-25-000143 · wk-form4_1755208864.xml · nonDerivative · entry 2 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,286.97 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $649.8492 to a high of $650.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 318 | $649.99 | $206,696.82 |
DisclosureSEC source: 0000874716-25-000143 · wk-form4_1755208864.xml · nonDerivative · entry 1 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,374.862 F1 · balance_after: Includes a total of 26.4960 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 13 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903 Underlying: Common Stock · 301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2025. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2025. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 94 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 12 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188 Underlying: Common Stock · 94 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2024. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2024. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 93 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 11 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92 Underlying: Common Stock · 93 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 69 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 10 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2022. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2022. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2022. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 177 | $444.53 | $78,681.81 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · nonDerivative · entry 5 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,216.3617 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · nonDerivative · entry 4 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,393.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 94 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · nonDerivative · entry 3 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,092.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 93 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · nonDerivative · entry 2 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,998.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 69 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · nonDerivative · entry 1 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,905.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 9 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 734 Underlying: Common Stock · 734 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 8 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 734 Underlying: Common Stock · 734 shares Expires not disclosed F3 · derivative.exercise_price: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.exercise_date: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.expiration_date: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.